Pharma Equity Group (“PEG” or “the Company”) presented a Q2-report characterized by further advancements in the clinical development (RNX-051), effective cost management, and an intensified focus on securing additional capital. The Company is evaluating options for a capital increase, which is essential for supporting further clinical advancements and for having the financial capacity to explore potential licensing agreements. In light of facing financial pressures, PEG demonstrated robust cost control, evidenced by a 1% increase in total operating expenses Y-Y and a -27% decrease Q-Q. Looking ahead, Analyst Group will monitor the continued clinical progression, the financial position, the EMA's decision regarding orphan drug designation for RNX-041, the receivable from Portinho S.A., and potential discussions with licensing partners concerning PEG’s strong portfolio of product candidates in Phase II. Analyst Group has made minor adjustments to the discount rate and forecasts, resulting in a revised potential present value of DKK 1.2 (1.4) per share in a Base scenario.